Drug Trial Radar · NCT06231550
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Mar 1, 2023
Primary completion
Mar 18, 2025
Study completion Mar 18, 2025
Sponsor
- Lead sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I clinical study to evaluate safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Axl inhibitor FC084CSA in patients with advanced malignant solid tumors who have failed standard anti-cancer treatment.
Conditions
- Advanced Malignant Solid Tumors
Interventions
FC084CSA tabletsDrug
FC084CSA accelerated doses at 100mg QD, and then started the conventional "3+3" design from 200mg QD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the Maximum Tolerated Dose (MTD)Time frame: Approximately 12 months
- Determine the Recommended Phase 2 Dose (RP2D)Time frame: Approximately 12 months
- Determine dose-limiting toxicity (DLT)Time frame: 24 days after first dose
- Frequency of adverse events (AEs) and SAEsTime frame: Approximately 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.